Blogs
Reliable immune profiling across global studies depends on methods that perform consistently, regardless of where they are run. We address this question in the white paper entitled “Cross-Site Validation of a 15-Color Spectral Cytometry Panel for Leukocyte Profiling,” documenting a global collaboration between KCAS Bio and its strategic partner,…
Posters & Papers
Discover in this white paper a global collaboration between KCAS Bio and its strategic partner, Crux Biolabs, to harmonize and validate a standardized 15-color spectral flow cytometry panel for pan-leukocyte profiling across multiple sites. If you have any questions about these services or any others offered by…
April 27
- April 28
KCAS Bio will be attending BioVaria in Munich, on April 27-28, 2026. This event connects leading tech transfer professionals and academic innovators with start-ups and representatives from the global biotech and pharma industry. Supporting Biologics Drug Development KCAS Bio supports small and large molecule drug development across preclinical and…
March 26
- March 26
KCAS Bio will be attending Innovation for Health in Utrecht, March 26, 2026. This events brings together key players from the Life Sciences & Health ecosystem. Centered on the theme “Bridging the Gap – From Idea to Innovation & from Patent to Patient,” the conference fosters insight sharing, collaboration, and…
April 21
- April 22
KCAS Bio will be attending German Biotech Days in Leipzig, on April 21–22, 2026. German Biotech Days (DBT) bring together entrepreneurs, scientists, and key partners from across the biotech ecosystem, including investors, funding institutions, policymakers, and public administration. Supporting Biologics Drug Development KCAS Bio supports small and large molecule…
March 24
- March 25
KCAS Bio will be attending NextGen Biomed 2026 in London, on March 24–25, 2026. NextGen Biomed is a long-standing, community-driven platform that brings together the biologics and immunotherapy ecosystem to foster interdisciplinary collaboration and knowledge sharing across the R&D lifecycle. Supporting Biologics Drug Development KCAS Bio supports biologics drug…
Podcasts
In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi…
Blogs
Developing anti-drug antibody (ADA) assays for therapeutic peptides can be complex, particularly when the molecule is small, endogenous-like, and when no positive control exists. This article describes the stepwise development of a screening and confirmatory ADA assay for a 47-amino-acid peptide targeting a receptor involved in inflammation in a…
Podcasts
In episode 28 of “The Conversational Flow”, our hosts, Adam and Brian, discuss why standardization is essential for credible flow cytometry data at scale. They walk through the biggest sources of variability – reagents and lots, sample handling and shipping time, anticoagulants and processing choices (whole blood vs. PBMCs, fresh…
March 24
- March 25
KCAS Bio will be attending Venture Connect in Durham, North Caroline on March 24-25, 2026. This event Brings together 200+ venture firms and capital sources to hear cutting-edge innovation in multiple verticals, and build strategic relationships that drive fundraising and business development. Venture Connect is the Southeast’s premier capital and…
April 30
- April 30
This new symposium series from PBSS will provide important value to life science industry scientists, since much of the R&D work of our industry nowadays is done at the vendors (CROs, CDMOs, tool makers etc). These scientific symposia will present unique technologies and valuable scientific case studies from vendor labs. …
Blogs
Bioanalysis sits at the intersection of science, regulation, and application. As therapeutic modalities grow more complex and development timelines compress, the role of bioanalysis continues to expand beyond data generation into strategic enablement. To better understand what lies ahead, we asked a diverse group of leaders across KCAS Bio, representing…